Patients will soon be enrolled for a global trial of an antibody treatment developed by Massachusetts-based Adagio Therapeutics called ADG20. The Phase 1/2/3 STAMP trial will test the effectiveness of the product to prevent hospitalizations and death in individuals at high risk who are experiencing mild or moderate disease symptoms. It can be administered as a single intramuscular dose in the outpatient setting and researchers are optimistic that it will be effective against variants.